Alimta (pemetrexed disodium; LY231514) : Lilly : Multitargeted antifolate

FDA Drug Approval Summaries: Pemetrexed (Alimta) (The Oncologist)
Hazarika, Maitreyee et al.
v.9, no.5 The Oncologist (Sept. 2004): 482-488
Reviews the efficacy and safety of pemetrexed (Alimta). Explains how Alimta works and discusses the common side effects and how to manage them. Discusses the rationale for FDA approval noting that it was based on superior survival as a clinical benefit. [9/04]

Pemetrexed (Alimta) is a Less-Toxic Alternative fore Recurrent Lung Cancer (National Cancer Institute)
Updates and discusses findings of a study initially reported at the 2003 ASCO annual meeting that found Alimta (pemetrexed) was as effective as the current standard therapy for recurrent NSCLC, but caused fewer side effects. [5/04]

Alimta - Recent MEDLINE Abstracts (PubMed)

Alimta - Clinical Trials (ClinicalTrials.gov)